Integrated BioPharma (INBP) Short Interest Ratio & Short Volume

Short interest is the volume of Integrated BioPharma shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 7,200 shares of INBP short. 0.07% of Integrated BioPharma's shares are currently sold short. Learn More on Integrated BioPharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.07% of Integrated BioPharma's floating shares are currently sold short.

Integrated BioPharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 7,200 shares, an increase of 350.0% from the previous total of 1,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.07% of Integrated BioPharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Integrated BioPharma: Prelude Therapeutics Incorporated (3.60%), Reviva Pharmaceuticals Holdings, Inc. (7.21%), Acrivon Therapeutics, Inc. (6.39%), Tenaya Therapeutics, Inc. (6.51%), Quince Therapeutics, Inc. (3.12%), Spero Therapeutics, Inc. (1.15%), Barinthus Biotherapeutics plc (0.14%), Alterity Therapeutics Limited (0.35%), Estrella Immunopharma, Inc. (0.21%), FibroBiologics, Inc. (5.36%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks.

Short selling INBP is an investing strategy that aims to generate trading profit from Integrated BioPharma as its price is falling. INBP shares are trading up $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Integrated BioPharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of INBP, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INBP, twice per month. The most recent reporting period available is April, 15 2025.